



Press Release

Half-Year Review of the Liquidity Agreement Entered into with TP ICAP (Europe) SA

Under the liquidity agreement covering the shares of ABIONYX Pharma (FR0012616852 – ABNX FP) entrusted to TP ICAP (Europe), the following assets were held in the liquidity account as of June 30, 2026:

- Number of shares: 118,866 shares
- Cash balance: €96,894.38

During the first half of 2026, a total of:

PURCHASES	282,460 shares	€933,897.51	361 transactions
SALE	226,618 securities	€782,823.64	283 transactions

It should be noted that as of the half-yearly balance sheet dated December 31, 2025, the following assets were recorded in the cash account:

- Number of shares: 63,024 shares
- Cash balance: €257,777.69

It is noted that upon the establishment of the liquidity agreement, the following assets were made available:

- Number of shares: 131,000 shares
- Cash balance: €40,801.20

APPENDIX H1 2026

ABNX FP	Purchases			Sales		
	Number of Transactions	Number of Securities	Capital in EUR	Number of Transactions	Number of securities	Capital in EUR
Total	361	282,460	933,897.51	283	226,618	783,823.64
20260101	0	0	0.00	0	0	0.00
20260102	1	1	3.86	6	6,971	27,579.56
20260105	5	7,061	26,946.26	1	1	3.96
20260106	2	2,051	7,527.21	2	871	3,266.21
20260107	3	2,711	10,063.36	3	1,811	6,909.36
20260108	4	4,091	15,043.56	1	1	3.76
20260109	1	1	3.64	3	1,941	7,152.84
20260112	1	1	3.68	3	1,881	7,082.18
20260113	2	1,991	7,267.22	3	949	3,541.20
20260114	4	4,061	14,770.64	1	1	3.74
20260115	1	1	3.62	3	1,981	7,221.02
20260116	1	1	3.64	4	3,771	13,941.24
20260119	4	4,151	15,089.66	3	1,821	6,874.46
20260120	4	3,951	14,564.30	1	1	3.70
20260121	3	2,481	9,085.50	1	1	3.70
20260122	1	1	3.79	5	6,071	23,288.19
20260123	3	2,521	9,660.60	5	5,521	22,070.20
20260126	4	3,841	15,378.82	2	891	3,688.72
20260127	3	2,441	9,671.28	1	1	3.98
20260128	2	1,751	6,846.45	2	224	893.72
20260129	4	3,531	13,678.17	2	366	1,460.32
20260130	3	2,251	8,535.84	1	1	3.84
20260202	1	1,600	6,032.00	2	1,061	4,084.78
20260203	2	1,561	5,963.08	3	2,171	8,499.88
20260204	3	2,171	8,210.75	1	1	3.85
20260205	4	3,221	11,908.74	1	1	3.74
20260206	4	3,071	11,200.58	1	1	3.68
20260209	3	1,921	6,957.99	1	1	3.69
20260210	1	1	3.67	4	4,821	17,847.67
20260211	4	3,071	11,169.88	1	1	3.68
20260212	1	1	3.55	2	1,181	4,251.55
20260213	3	1,991	7,092.01	1	1	3.61
20260216	5	4,406	15,279.94	1	1	3.59
20260217	1	1	3.43	2	1,251	4,365.93
20260218	3	1,851	6,376.19	1	1	3.49
20260219	4	2,721	9,257.88	1	1	3.48
20260220	4	2,581	8,678.29	1	1	3.39
20260223	5	3,697	12,071.27	3	2,701	9,237.73
20260224	4	2,411	7,986.25	1	1	3.35
20260225	3	1,521	4,920.08	1	1	3.28
20260226	1	1	3.27	3	2,841	9,347.27

20260227	1	1	3.34	4	5,441	18,496.64
20260302	6	5,511	17,690.22	1	1	3.22
20260303	6	4,901	15,838.37	1	1	3.37
20260304	1	1	3.16	5	8,471	27,722.36
20260305	2	501	1,628.33	3	2,661	8,888.13
20260306	2	1,351	4,336.79	3	2,611	8,616.59
20260309	4	2,831	9,178.97	2	1,261	4,224.27
20260310	1	1	3.34	6	9,651	32,795.94
20260311	4	3,241	10,929.88	1	1	3.48
20260312	2	1,491	4,965.10	2	1,191	4,061.30
20260313	4	3,091	10,199.83	1	1	3.33
20260316	3	1,961	6,323.71	3	1,650	5,469.48
20260317	1	1	3.27	3	2,561	8,579.67
20260318	3	1,991	6,619.47	1	1	3.37
20260319	4	2,971	9,633.40	1	1	3.30
20260320	2	1,391	4,381.70	2	1,291	4,169.90
20260323	4	2,911	8,935.88	4	2,779	8,930.84
20260324	4	2,881	8,995.93	2	1,291	4,169.93
20260325	2	1,371	4,250.16	1	1	3.16
20260326	5	4,311	12,983.99	1	1	3.09
20260327	1	1	3.25	11	23,201	76,137.55
20260330	1	1	3.97	10	15,501	61,966.67
20260331	5	6,751	24,540.66	1	1	3.66
20260401	3	2,671	9,701.24	4	3,771	14,224.24
20260402	3	2,691	9,800.85	1	1	3.65
20260403	0	0	0.00	0	0	0.00
20260406	0	0	0.00	0	0	0.00
20260407	1	1	3.70	1	1	3.70
20260408	1	1	3.61	6	7,201	26,219.81
20260409	3	2,931	10,498.91	1	1	3.61
20260410	1	1	3.57	2	911	3,288.67
20260413	4	4,351	15,391.96	1	1	3.56
20260414	2	954	3,377.22	5	5,701	21,042.10
20260415	1	1	3.76	5	5,301	20,414.16
20260416	3	2,921	11,105.66	2	821	3,193.66
20260417	1	1	3.81	5	5,031	19,675.91
20260420	4	4,551	17,398.14	1	1	3.84
20260421	4	4,411	16,463.56	1	1	3.76
20260422	3	2,781	10,211.94	1	1	3.74
20260423	2	1,981	7,191.04	1	1	3.64
20260424	4	4,011	14,348.32	1	1	3.62
20260427	3	2,318	8,214.59	1	1	3.55
20260428	3	2,421	8,551.15	2	1,061	3,840.75
20260429	3	2,411	8,401.70	2	1,081	3,891.60
20260430	3	2,381	8,201.90	1	1	3.50
20260501	0	0	0.00	0	0	0.00
20260504	3	2,311	7,868.36	2	1,131	3,947.16

20260505	3	2,291	7,708.49	3	2,311	7,996.29
20260506	1	1	3.42	5	6,801	23,821.12
20260507	1	1	3.59	5	6,281	22,994.29
20260508	3	2,701	9,621.00	2	961	3,507.60
20260511	1	1	3.57	4	3,941	14,254.37
20260512	3	2,781	9,933.83	3	1,901	6,986.43
20260513	1	1	3.68	4	3,751	14,017.48
20260514	1	1	3.71	3	1,811	6,746.41
20260515	3	2,911	10,660.27	1	1	3.67
20260518	4	4,411	15,514.43	1	1	3.63
20260519	1	1	3.50	1	1	3.50
20260520	3	2,751	9,606.66	1	1	3.56
20260521	4	4,011	13,947.22	1	1	3.52
20260522	4	3,911	13,111.16	3	2,151	7,464.26
20260525	1	1	3.37	4	4,321	14,905.17
20260526	2	914	3,116.80	2	1,031	3,598.17
20260527	11	17,411	53,176.77	1	1	3.07
20260528	6	7,131	21,135.56	1	1	3.06
20260529	3	2,111	6,005.20	1	1	2.90
20260601	3	2,041	5,765.23	2	1,401	4,048.83
20260602	4	2,390	6,659.66	1	1	2.80
20260603	3	1,961	5,407.18	1	1	2.78
20260604	4	2,881	7,839.44	1	1	2.74
20260605	1	1	2.72	4	6,011	16,557.92
20260608	3	2,041	5,546.13	1	1	2.73
20260609	3	1,971	5,296.83	2	1,461	4,017.73
20260610	3	1,961	5,250.31	1	1	2.71
20260611	1	1	2.66	2	1,491	4,010.76
20260612	1	1	2.72	3	2,961	8,068.92
20260615	3	2,061	5,538.66	2	1,421	3,914.86
20260616	5	4,901	12,736.29	1	1	2.69
20260617	1	1	2.56	3	1,511	3,868.36
20260618	10	10,945	25,700.63	1	1	2.37
20260619	4	2,791	6,152.77	1	1	2.27
20260622	1	1	2.22	1	1	2.22
20260623	2	1,041	2,290.23	1	1	2.23
20260624	4	2,571	5,642.25	1	1	2.25
20260625	6	3,842	8,014.42	1	1	2.09
20260626	4	2,351	4,783.08	1	1	2.08
20260629	2	1,081	2,172.85	2	1,801	3,728.05
20260630	2	29	58.88	5	10,571	22,546.84

About ABIONYX Pharma

ABIONYX Pharma is a next-generation biopharmaceutical company focused on sepsis and critical care, developing breakthrough biotherapies for serious diseases for which there are no effective treatments. Through its proprietary apoA-I-based technology platform, ABIONYX Pharma designs innovative biopharmaceuticals and next-generation HDL vectors that target the immune-inflammatory dysregulation at the heart of sepsis and other severe diseases. Driven by recognized scientific expertise, a differentiated pipeline, and an expanding global clinical network, ABIONYX Pharma aims to redefine therapeutic standards for sepsis and become a key player in intensive care.

Contacts:

ABIONYX Pharma
infos@abionyx.com